GMTech Inc. Announces the Launch of NEW WEB3 Smartphone
HONG KONG / ACCESS Newswire / May 30, 2025 / Shenggang Excellence Limited, a wholly-owned subsidiary of global technology giant GMTECH INC. (OTC Pink:GMTH), announced that it will once again launch a new generation of Web3 native smart terminals. This new model has achieved multiple breakthroughs based on the previous generation of technology and officially entered the next stage of decentralized smart terminals.
The new device integrates three core modules: DePIN (decentralized Internet of Things), DID (on-chain identity), and edge AI computing, and for the first time realizes lightweight consensus operation and multi-chain ecological compatibility under the 'hardware as node' architecture. It supports native custody of on-chain assets, encrypted communication, distributed storage links and other functions, and is committed to creating a truly 'chain-born' user operating system.
Compared with the first EARSON, this product has been comprehensively upgraded in terms of processor performance, node capacity, battery life and ecological compatibility, and will be officially launched in core markets such as Asia and the Middle East.
Juan Yang, CEO of GMTECH INC., said: 'We believe that the launch of this product will not only significantly promote the popularization of Web3 smart terminals, but also inspire users around the world to have a new understanding of the decentralized ecological entrance. We have observed that the Web3 and DePIN tracks are developing rapidly, and according to third-party forecasts, their overall market value is expected to exceed 10 trillion Hong Kong dollars by 2030. In response, our goal is not only to launch a device, but also to open a portal to the next generation of the Internet.'
Currently, Shenggang Excellence has established a deep cooperation framework with many leading public chains, distributed payment and storage projects, and is building a complete chain ecosystem around the terminal covering multiple scenarios such as wallets, security, payment, and social networking.
Juan Yang further pointed out: 'This launch represents Shenggang Excellence's transformation from a 'smartphone manufacturer' to a 'decentralized ecological infrastructure builder', and is also another strategic leap achieved by its parent company GMTECH INC. in the field of smart hardware and blockchain integration. The launch of this product will further consolidate GMTECH INC.'s leading position in the next-generation Internet technology landscape and inject new growth momentum into its global technology market valuation system.'
About GMTech Inc.
GMTech Inc. is a technology company providing IT consulting services to clients and is also expanding its business to design and development of smartphone with WEB3 elements integrated through its wholly owned Hong Kong subsidiary, Shenggang Excellence Limited.
Forward-Looking Statements
This press release contains information about the Company's view of its future expectations, plans and prospects that constitute 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance and reflect the current view about future events. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Therefore, you should not rely on any of these forward-looking statements. The Company encourages you to review other factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
For more information, please contact:
[email protected]
SOURCE: GMTech Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Iran boosts highly enriched uranium production: IAEA
Iran has ramped up production of highly enriched uranium, according to a confidential UN watchdog report, as Tehran said Saturday that it had received US proposals to settle its long-running nuclear dispute with the West. Iran rejected the report by the International Atomic Energy Agency (IAEA), the latest move in years-long efforts to restrict its nuclear activities over fears that it is seeking to develop nuclear weapons. The IAEA report, seen by AFP, said Iran had sharply increased its stockpile of uranium enriched to up to 60 percent, close to the roughly 90 percent level needed for atomic weapons. Iran rejected the report, which came amid high tensions in the Middle East over Israel's military offensive in Gaza, with Tehran's foreign ministry calling it a "political" manoeuvre. The ministry accused Israel of providing "unreliable and misleading information" to the IAEA for the report, "contrary to the IAEA's principles of professional verification". Iran's Foreign Minister Abbas Araghchi said earlier Saturday that he had received "elements" of a US proposal for a potential nuclear deal following five rounds of talks mediated by Oman. Omani Foreign Minister Badr al-Busaidi "paid a short visit to Tehran today to present elements of a US proposal which will be appropriately responded to in line with the principles, national interests and rights of the people of Iran," Araghchi said on X. The IAEA report said Iran had an estimated 408.6 kilogrammes of uranium enriched to up to 60 percent as of May 17, up by 133.8 kilogrammes since the last report in February. Iran's total amount of enriched uranium now exceeds 45 times the limit authorised by the 2015 agreement with world powers, and is estimated at 9,247.6 kilogrammes. "The significantly increased production and accumulation of highly enriched uranium by Iran, the only non-nuclear weapon State to produce such nuclear material, is of serious concern," the IAEA said. In a separate in-depth report, the IAEA criticised "less than satisfactory" cooperation from Tehran over its scrutiny of its nuclear programme, specifically noting Iran's lack of progress in explaining nuclear material found at undeclared sites. - Iran says nuclear arms 'unacceptable' - Western governments have long suspected Iran of seeking to develop a nuclear weapons capability to counter the widely suspected but undeclared arsenal of its arch-foe Israel. Iran has denied seeking nuclear arms and says it needs the uranium for civilian power production. Following the IAEA report, Israel on Saturday accused Iran of being "totally determined" to acquire nuclear weapons. "Such a level of enrichment exists only in countries actively pursuing nuclear weapons and has no civilian justification whatsoever," a statement from Prime Minister Benjamin Netanyahu's office said. In response, Araghchi reaffirmed the country's longstanding position, saying Tehran rejected nuclear weapons. "If the issue is nuclear weapons, yes, we too consider this type of weapon unacceptable," Araghchi, Iran's lead negotiator in the talks, said in a televised speech. "We agree with them on this issue." Araghchi's remarks came a day after US President Donald Trump said Iran "cannot have a nuclear weapon", while expressing hope of striking a deal soon. On Thursday, Araghchi hit out at what he called "media speculation" that the two sides were close to an agreement, saying he was "not sure if" a deal was "imminent". Iran has held five rounds of talks with the United States on a new agreement with major powers after Trump abandoned the process during his first term as president in 2018. No date or venue has yet been announced for the next round but Araghchi said Wednesday that he expected an announcement from mediator Oman in the "next few days". Washington has said Iran's uranium programme must cease but Tehran insists it has a right to pursue it under the nuclear Non-Proliferation Treaty. - 'Very good talks' - Israel has repeatedly threatened military action, after pummelling Iranian air defences during two exchanges of fire last year. Trump said Wednesday that the United States was having "very good talks with Iran", adding that he had warned Netanyahu against striking its nuclear facilities as it would not be "appropriate right now". Trump has not ruled out military action but said he wants space to make a deal first, and has also said that Israel, and not the United States, would take the lead in any such strikes. Trump adopted a "maximum pressure" policy against Tehran after abandoning the 2015 agreement and reimposed sweeping sanctions which the deal had lifted in return for UN-monitored restrictions on Iran's nuclear activities. Iran continued to honour the agreement for a year, but then began rolling back its own compliance with its terms. Uranium enriched to up to 60 percent is far beyond the 3.67-percent limit set by the 2015 agreement. In recent days, Tehran has said that if a deal is reached, it may consider allowing US inspectors to join the IAEA monitoring teams. sbr-ap-kym/rlp/js
Yahoo
2 hours ago
- Yahoo
Toyota's 2026 Camry: Now With 100% More Sass and Attitude
Toyota's bringing the Nightshade trim to the 2026 Camry, and it's more than just a style play. It's still hybrid-only, which means top-tier fuel economy without sacrificing punch. This ninth-gen Camry shows up with sharp new looks and performance tweaks that go beyond surface level. It's got a revamped powertrain, electric all-wheel drive, and those stealthy blacked-out Nightshade vibes. This isn't the Camry you remember from family road trips. Whether you're chasing efficiency, edge, or a solid daily driver, the 2026 Camry might catch you off guard—in a good way. Toyota's best-selling sedan is turning up the attitude for 2026 with the new Camry Nightshade Edition. This stealthy, aggressive trim joins the ninth-generation lineup with a fresh dose of edge. Built on Toyota's all-hybrid Camry platform, the Nightshade stands out with blacked-out details, 19-inch black alloy wheels, and Midnight Black Metallic accents everywhere from the grille to the diffuser. It comes in three bold color options: Ice Cap, Supersonic Red, and Midnight Black Metallic—each pairing eye-catching design with hybrid efficiency. Under the hood, every 2026 Camry gets Toyota's fifth-gen hybrid system, combining a 2.5-liter 4-cylinder engine with an electric motor. It delivers 225 horsepower in front-wheel drive and 232 in all-wheel drive. Toyota has tweaked the setup for smoother, more natural acceleration. Plus, a recalibrated e-CVT improves throttle response while keeping fuel economy sky-high—up to 51 mpg combined in the FWD LE model. For extra traction and peace of mind, Electronic On-Demand AWD is now available on all five Camry trims—LE, SE, XLE, XSE, and Nightshade. Instead of a mechanical driveshaft, it uses a rear-mounted electric motor, making the system lighter, quicker to respond, and 30 horsepower stronger than before. Whether you're navigating slick roads or winding backroads, the AWD setup helps deliver better grip, stability, and sharper steering. It's smart enough to send torque where it's needed, exactly when it's needed. Design-wise, the 2026 Camry gets a serious glow-up. Created by CALTY Design Studios in California and Michigan, the new look includes a bold hammerhead front fascia, standard LED lighting, and a lower, more streamlined stance. Each trim brings its own flair with unique grille and wheel designs. The SE and XSE trims go sportier with mesh grilles, dual exhaust tips, aerodynamic accents, and blacked-out details—plus, the XSE adds a slick two-tone option with a black roof and bold colors like Supersonic Red and the new Dark Cosmos. Inside, each Camry trim brings its own vibe—from the LE's clean, minimalist layout to the XLE's more premium feel with upscale materials. Sportier models like the SE and XSE add flair with contrast stitching, paddle shifters, and supportive bolstered seats. Across the board, the 2026 Camry is packed with standard tech and safety features. Toyota's newest infotainment system comes with an 8-inch screen or an optional 12.3-inch upgrade for those who want a bit more. We already love what Toyota did with the 2025 Prius Nightshade, and the Camry seems ready to follow suit. The full 2026 Camry lineup, including the sleek Nightshade Edition, lands in dealerships fall 2025—with pricing to be revealed closer to launch. With bold styling, improved hybrid power, and optional all-wheel drive, this is the most capable Camry yet. And for those craving something with a little more attitude, the Nightshade might just be the one to watch. Source: Toyota, HotCars
Yahoo
2 hours ago
- Yahoo
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING, May 31, 2025--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ("Avistone"), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 studyAbstract Number For Publication: 8632Session: Poster Session-Lung Cancer- Non-Small Cell MetastaticLocation: Poster Board, 112Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common "off-target" mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ("Avistone") is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors. View source version on Contacts BD@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
